Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR T-Cell Therapy LEU011

  • Company on-track to dose first patient in LEU011 Phase 1/2 AERIAL trial during the fourth quarter of 2023
  • Lead programme, LEU011 previously awarded an Innovation Passport by MHRA for the treatment of solid tumours expressing NKG2D ligands

London, UK – 21 September 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorisation (CTA) to commence the Phase 1/2 AERIAL clinical trial evaluating the safety and tolerability of LEU011 for the treatment of adults with relapsed or refractory solid tumours.

Read more…